Supplementation with a probiotic mixture accelerates gut microbiome maturation and reduces intestinal inflammation in extremely preterm infants

Jumana Samara; Shirin Moossavi; Belal Alshaikh; Van A. Ortega; Veronika Kuchařová Pettersen; Tahsin Ferdous; Suzie L. Hoops; Amuchou Soraisham; Joseph Vayalumkal; Deonne Dersch-Mills; Jeffrey S. Gerber; Sagori Mukhopadhyay; Karen Puopolo; Thomas A. Tompkins; Dan Knights; Jens Walter; Harish Amin; Marie Claire Arrieta

doi:10.1016/j.chom.2022.04.005

Supplementation with a probiotic mixture accelerates gut microbiome maturation and reduces intestinal inflammation in extremely preterm infants

Jumana Samara, Shirin Moossavi, Belal Alshaikh, Van A. Ortega, Veronika Kuchařová Pettersen, Tahsin Ferdous, Suzie L. Hoops, Amuchou Soraisham, Joseph Vayalumkal, Deonne Dersch-Mills, Jeffrey S. Gerber, Sagori Mukhopadhyay, Karen Puopolo, Thomas A. Tompkins, Dan Knights, Jens Walter, Harish Amin, Marie Claire Arrieta

Research output: Contribution to journal › Article › peer-review

60 Scopus citations

Abstract

Probiotics are increasingly administered to premature infants to prevent necrotizing enterocolitis and neonatal sepsis. However, their effects on gut microbiome assembly and immunity are poorly understood. Using a randomized intervention trial in extremely premature infants, we tested the effects of a probiotic product containing four strains of Bifidobacterium species autochthonous to the infant gut and one Lacticaseibacillus strain on the compositional and functional trajectory of microbiome. Daily administration of the mixture accelerated the transition into a mature, term-like microbiome with higher stability and species interconnectivity. Besides infant age, Bifidobacterium strains and stool metabolites were the best predictors of microbiome maturation, and structural equation modeling confirmed probiotics as a major determinant for the trajectory of microbiome assembly. Bifidobacterium-driven microbiome maturation was also linked to an anti-inflammatory intestinal immune milieu. This demonstrates that Bifidobacterium strains are ecosystem engineers that lead to an acceleration of microbiome maturation and immunological consequences in extremely premature infants.

Original language	English (US)
Pages (from-to)	696-711.e5
Journal	Cell Host and Microbe
Volume	30
Issue number	5
DOIs	https://doi.org/10.1016/j.chom.2022.04.005
State	Published - May 11 2022
Externally published	Yes

Bibliographical note

Funding Information:
The authors would like to acknowledge study participants and their families for their support to research, as well as NICU nurses for their effort in sample collection and communication with the study group. The following collaborators supported clinical and laboratory aspects of this research: Rachel Sheinfeld, Erik van Tilburg Bernardes, Mackenzie Gutierrez, Kristen Kalbfleisch, Julia Gorospe, Amanda Piano, Dr. Neha Bansal, Marija Drikic, and Ryan Groves. This work was supported by funds from the Cumming School of Medicine, the Alberta Children Hospital Research Institute, the Snyder Institute of Chronic Diseases, the Canadian Institutes for Health Research. The International Microbiome Center is supported by the Cumming School of Medicine, University of Calgary, Western Economic Diversification and Alberta Economic Development, and Trade, Canada. S. Moossavi is supported by CIHR and Killam Postdoctoral Fellowship. V.A.O. is supported by a MITACS Elevate Fellowship. J.W. acknowledges support by Science Foundation Ireland (SFI) through an SFI Professorship (19/RP/6853) and a Centre award (APC/SFI/12/RC/2273_P2) to the APC Microbiome Ireland. H.A. B.A. A.S. J.V. and D.D.-M. contributed to the design of the premature RCT study. J.S. and B.A. monitored the clinical trial. J.S. communicated with study participant families, conducted study interviews, and compilated all clinical data. J.S. V.K.P. and V.A.O. prepared all the samples for sequencing and metabolomics analysis. J.S. carried out qPCR analysis. S. Moossavi, J.S. and M.-C.A. analyzed the 16S and ITS2 sequences. S. Moossavi, J.S. V.A.O. and V.K.P. analyzed the metabolomics data. S. Moossavi and T.F. carried out statistical analysis. V.A.O. performed immune and protein determination assays. S. Moossavi and M.-C.A. created the paper figures. T.A.T. provided probiotic strains and with J.W. guidance on qPCR protocol. S.L.H. D.K. J.S.G. S. Mukhopadhyay, and K.P. provided the 16S sequences from the MAGIC Study. M.-C.A. S. Moossavi, J.S. and J.W. contributed to data interpretation and writing the first and subsequent drafts of the manuscript. All authors edited the manuscript and contributed extensively to the work presented here. T.A.T. was the Research Director at Lallemand Health Solutions, the manufacturers of FloraBABY. The other authors declare no competing interests.

Funding Information:
The authors would like to acknowledge study participants and their families for their support to research, as well as NICU nurses for their effort in sample collection and communication with the study group. The following collaborators supported clinical and laboratory aspects of this research: Rachel Sheinfeld, Erik van Tilburg Bernardes, Mackenzie Gutierrez, Kristen Kalbfleisch, Julia Gorospe, Amanda Piano, Dr. Neha Bansal, Marija Drikic, and Ryan Groves. This work was supported by funds from the Cumming School of Medicine , the Alberta Children Hospital Research Institute , the Snyder Institute of Chronic Diseases , the Canadian Institutes for Health Research . The International Microbiome Center is supported by the Cumming School of Medicine, University of Calgary , Western Economic Diversification and Alberta Economic Development , and Trade, Canada. S. Moossavi is supported by CIHR and Killam Postdoctoral Fellowship. V.A.O. is supported by a MITACS Elevate Fellowship. J.W. acknowledges support by Science Foundation Ireland (SFI) through an SFI Professorship ( 19/RP/6853 ) and a Centre award ( APC/SFI/12/RC/2273_P2 ) to the APC Microbiome Ireland .

Publisher Copyright:
© 2022 Elsevier Inc.

Keywords

immune priming
maturation
microbiome
mycobiome
premature infant
probiotic

PubMed: MeSH publication types

Journal Article
Randomized Controlled Trial

Access

10.1016/j.chom.2022.04.005

OpenUrl availability

Full text

Cite this

Samara, J., Moossavi, S., Alshaikh, B., Ortega, V. A., Pettersen, V. K., Ferdous, T., Hoops, S. L., Soraisham, A., Vayalumkal, J., Dersch-Mills, D., Gerber, J. S., Mukhopadhyay, S., Puopolo, K., Tompkins, T. A., Knights, D., Walter, J., Amin, H., & Arrieta, M. C. (2022). Supplementation with a probiotic mixture accelerates gut microbiome maturation and reduces intestinal inflammation in extremely preterm infants. Cell Host and Microbe, 30(5), 696-711.e5. https://doi.org/10.1016/j.chom.2022.04.005

Samara, J, Moossavi, S, Alshaikh, B, Ortega, VA, Pettersen, VK, Ferdous, T, Hoops, SL, Soraisham, A, Vayalumkal, J, Dersch-Mills, D, Gerber, JS, Mukhopadhyay, S, Puopolo, K, Tompkins, TA, Knights, D, Walter, J, Amin, H & Arrieta, MC 2022, 'Supplementation with a probiotic mixture accelerates gut microbiome maturation and reduces intestinal inflammation in extremely preterm infants', Cell Host and Microbe, vol. 30, no. 5, pp. 696-711.e5. https://doi.org/10.1016/j.chom.2022.04.005

@article{673d0182f4bf452aa286bcb2ef8088d2,

title = "Supplementation with a probiotic mixture accelerates gut microbiome maturation and reduces intestinal inflammation in extremely preterm infants",

abstract = "Probiotics are increasingly administered to premature infants to prevent necrotizing enterocolitis and neonatal sepsis. However, their effects on gut microbiome assembly and immunity are poorly understood. Using a randomized intervention trial in extremely premature infants, we tested the effects of a probiotic product containing four strains of Bifidobacterium species autochthonous to the infant gut and one Lacticaseibacillus strain on the compositional and functional trajectory of microbiome. Daily administration of the mixture accelerated the transition into a mature, term-like microbiome with higher stability and species interconnectivity. Besides infant age, Bifidobacterium strains and stool metabolites were the best predictors of microbiome maturation, and structural equation modeling confirmed probiotics as a major determinant for the trajectory of microbiome assembly. Bifidobacterium-driven microbiome maturation was also linked to an anti-inflammatory intestinal immune milieu. This demonstrates that Bifidobacterium strains are ecosystem engineers that lead to an acceleration of microbiome maturation and immunological consequences in extremely premature infants.",

keywords = "immune priming, maturation, microbiome, mycobiome, premature infant, probiotic",

author = "Jumana Samara and Shirin Moossavi and Belal Alshaikh and Ortega, {Van A.} and Pettersen, {Veronika Kucha{\v r}ov{\'a}} and Tahsin Ferdous and Hoops, {Suzie L.} and Amuchou Soraisham and Joseph Vayalumkal and Deonne Dersch-Mills and Gerber, {Jeffrey S.} and Sagori Mukhopadhyay and Karen Puopolo and Tompkins, {Thomas A.} and Dan Knights and Jens Walter and Harish Amin and Arrieta, {Marie Claire}",

note = "Funding Information: The authors would like to acknowledge study participants and their families for their support to research, as well as NICU nurses for their effort in sample collection and communication with the study group. The following collaborators supported clinical and laboratory aspects of this research: Rachel Sheinfeld, Erik van Tilburg Bernardes, Mackenzie Gutierrez, Kristen Kalbfleisch, Julia Gorospe, Amanda Piano, Dr. Neha Bansal, Marija Drikic, and Ryan Groves. This work was supported by funds from the Cumming School of Medicine, the Alberta Children Hospital Research Institute, the Snyder Institute of Chronic Diseases, the Canadian Institutes for Health Research. The International Microbiome Center is supported by the Cumming School of Medicine, University of Calgary, Western Economic Diversification and Alberta Economic Development, and Trade, Canada. S. Moossavi is supported by CIHR and Killam Postdoctoral Fellowship. V.A.O. is supported by a MITACS Elevate Fellowship. J.W. acknowledges support by Science Foundation Ireland (SFI) through an SFI Professorship (19/RP/6853) and a Centre award (APC/SFI/12/RC/2273_P2) to the APC Microbiome Ireland. H.A. B.A. A.S. J.V. and D.D.-M. contributed to the design of the premature RCT study. J.S. and B.A. monitored the clinical trial. J.S. communicated with study participant families, conducted study interviews, and compilated all clinical data. J.S. V.K.P. and V.A.O. prepared all the samples for sequencing and metabolomics analysis. J.S. carried out qPCR analysis. S. Moossavi, J.S. and M.-C.A. analyzed the 16S and ITS2 sequences. S. Moossavi, J.S. V.A.O. and V.K.P. analyzed the metabolomics data. S. Moossavi and T.F. carried out statistical analysis. V.A.O. performed immune and protein determination assays. S. Moossavi and M.-C.A. created the paper figures. T.A.T. provided probiotic strains and with J.W. guidance on qPCR protocol. S.L.H. D.K. J.S.G. S. Mukhopadhyay, and K.P. provided the 16S sequences from the MAGIC Study. M.-C.A. S. Moossavi, J.S. and J.W. contributed to data interpretation and writing the first and subsequent drafts of the manuscript. All authors edited the manuscript and contributed extensively to the work presented here. T.A.T. was the Research Director at Lallemand Health Solutions, the manufacturers of FloraBABY. The other authors declare no competing interests. Funding Information: The authors would like to acknowledge study participants and their families for their support to research, as well as NICU nurses for their effort in sample collection and communication with the study group. The following collaborators supported clinical and laboratory aspects of this research: Rachel Sheinfeld, Erik van Tilburg Bernardes, Mackenzie Gutierrez, Kristen Kalbfleisch, Julia Gorospe, Amanda Piano, Dr. Neha Bansal, Marija Drikic, and Ryan Groves. This work was supported by funds from the Cumming School of Medicine , the Alberta Children Hospital Research Institute , the Snyder Institute of Chronic Diseases , the Canadian Institutes for Health Research . The International Microbiome Center is supported by the Cumming School of Medicine, University of Calgary , Western Economic Diversification and Alberta Economic Development , and Trade, Canada. S. Moossavi is supported by CIHR and Killam Postdoctoral Fellowship. V.A.O. is supported by a MITACS Elevate Fellowship. J.W. acknowledges support by Science Foundation Ireland (SFI) through an SFI Professorship ( 19/RP/6853 ) and a Centre award ( APC/SFI/12/RC/2273_P2 ) to the APC Microbiome Ireland . Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = may,

day = "11",

doi = "10.1016/j.chom.2022.04.005",

language = "English (US)",

volume = "30",

pages = "696--711.e5",

journal = "Cell Host and Microbe",

issn = "1931-3128",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - Supplementation with a probiotic mixture accelerates gut microbiome maturation and reduces intestinal inflammation in extremely preterm infants

AU - Samara, Jumana

AU - Moossavi, Shirin

AU - Alshaikh, Belal

AU - Ortega, Van A.

AU - Pettersen, Veronika Kuchařová

AU - Ferdous, Tahsin

AU - Hoops, Suzie L.

AU - Soraisham, Amuchou

AU - Vayalumkal, Joseph

AU - Dersch-Mills, Deonne

AU - Gerber, Jeffrey S.

AU - Mukhopadhyay, Sagori

AU - Puopolo, Karen

AU - Tompkins, Thomas A.

AU - Knights, Dan

AU - Walter, Jens

AU - Amin, Harish

AU - Arrieta, Marie Claire

N1 - Funding Information: The authors would like to acknowledge study participants and their families for their support to research, as well as NICU nurses for their effort in sample collection and communication with the study group. The following collaborators supported clinical and laboratory aspects of this research: Rachel Sheinfeld, Erik van Tilburg Bernardes, Mackenzie Gutierrez, Kristen Kalbfleisch, Julia Gorospe, Amanda Piano, Dr. Neha Bansal, Marija Drikic, and Ryan Groves. This work was supported by funds from the Cumming School of Medicine, the Alberta Children Hospital Research Institute, the Snyder Institute of Chronic Diseases, the Canadian Institutes for Health Research. The International Microbiome Center is supported by the Cumming School of Medicine, University of Calgary, Western Economic Diversification and Alberta Economic Development, and Trade, Canada. S. Moossavi is supported by CIHR and Killam Postdoctoral Fellowship. V.A.O. is supported by a MITACS Elevate Fellowship. J.W. acknowledges support by Science Foundation Ireland (SFI) through an SFI Professorship (19/RP/6853) and a Centre award (APC/SFI/12/RC/2273_P2) to the APC Microbiome Ireland. H.A. B.A. A.S. J.V. and D.D.-M. contributed to the design of the premature RCT study. J.S. and B.A. monitored the clinical trial. J.S. communicated with study participant families, conducted study interviews, and compilated all clinical data. J.S. V.K.P. and V.A.O. prepared all the samples for sequencing and metabolomics analysis. J.S. carried out qPCR analysis. S. Moossavi, J.S. and M.-C.A. analyzed the 16S and ITS2 sequences. S. Moossavi, J.S. V.A.O. and V.K.P. analyzed the metabolomics data. S. Moossavi and T.F. carried out statistical analysis. V.A.O. performed immune and protein determination assays. S. Moossavi and M.-C.A. created the paper figures. T.A.T. provided probiotic strains and with J.W. guidance on qPCR protocol. S.L.H. D.K. J.S.G. S. Mukhopadhyay, and K.P. provided the 16S sequences from the MAGIC Study. M.-C.A. S. Moossavi, J.S. and J.W. contributed to data interpretation and writing the first and subsequent drafts of the manuscript. All authors edited the manuscript and contributed extensively to the work presented here. T.A.T. was the Research Director at Lallemand Health Solutions, the manufacturers of FloraBABY. The other authors declare no competing interests. Funding Information: The authors would like to acknowledge study participants and their families for their support to research, as well as NICU nurses for their effort in sample collection and communication with the study group. The following collaborators supported clinical and laboratory aspects of this research: Rachel Sheinfeld, Erik van Tilburg Bernardes, Mackenzie Gutierrez, Kristen Kalbfleisch, Julia Gorospe, Amanda Piano, Dr. Neha Bansal, Marija Drikic, and Ryan Groves. This work was supported by funds from the Cumming School of Medicine , the Alberta Children Hospital Research Institute , the Snyder Institute of Chronic Diseases , the Canadian Institutes for Health Research . The International Microbiome Center is supported by the Cumming School of Medicine, University of Calgary , Western Economic Diversification and Alberta Economic Development , and Trade, Canada. S. Moossavi is supported by CIHR and Killam Postdoctoral Fellowship. V.A.O. is supported by a MITACS Elevate Fellowship. J.W. acknowledges support by Science Foundation Ireland (SFI) through an SFI Professorship ( 19/RP/6853 ) and a Centre award ( APC/SFI/12/RC/2273_P2 ) to the APC Microbiome Ireland . Publisher Copyright: © 2022 Elsevier Inc.

PY - 2022/5/11

Y1 - 2022/5/11

N2 - Probiotics are increasingly administered to premature infants to prevent necrotizing enterocolitis and neonatal sepsis. However, their effects on gut microbiome assembly and immunity are poorly understood. Using a randomized intervention trial in extremely premature infants, we tested the effects of a probiotic product containing four strains of Bifidobacterium species autochthonous to the infant gut and one Lacticaseibacillus strain on the compositional and functional trajectory of microbiome. Daily administration of the mixture accelerated the transition into a mature, term-like microbiome with higher stability and species interconnectivity. Besides infant age, Bifidobacterium strains and stool metabolites were the best predictors of microbiome maturation, and structural equation modeling confirmed probiotics as a major determinant for the trajectory of microbiome assembly. Bifidobacterium-driven microbiome maturation was also linked to an anti-inflammatory intestinal immune milieu. This demonstrates that Bifidobacterium strains are ecosystem engineers that lead to an acceleration of microbiome maturation and immunological consequences in extremely premature infants.

AB - Probiotics are increasingly administered to premature infants to prevent necrotizing enterocolitis and neonatal sepsis. However, their effects on gut microbiome assembly and immunity are poorly understood. Using a randomized intervention trial in extremely premature infants, we tested the effects of a probiotic product containing four strains of Bifidobacterium species autochthonous to the infant gut and one Lacticaseibacillus strain on the compositional and functional trajectory of microbiome. Daily administration of the mixture accelerated the transition into a mature, term-like microbiome with higher stability and species interconnectivity. Besides infant age, Bifidobacterium strains and stool metabolites were the best predictors of microbiome maturation, and structural equation modeling confirmed probiotics as a major determinant for the trajectory of microbiome assembly. Bifidobacterium-driven microbiome maturation was also linked to an anti-inflammatory intestinal immune milieu. This demonstrates that Bifidobacterium strains are ecosystem engineers that lead to an acceleration of microbiome maturation and immunological consequences in extremely premature infants.

KW - immune priming

KW - maturation

KW - microbiome

KW - mycobiome

KW - premature infant

KW - probiotic

UR - http://www.scopus.com/inward/record.url?scp=85129576880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129576880&partnerID=8YFLogxK

U2 - 10.1016/j.chom.2022.04.005

DO - 10.1016/j.chom.2022.04.005

M3 - Article

C2 - 35550672

AN - SCOPUS:85129576880

SN - 1931-3128

VL - 30

SP - 696-711.e5

JO - Cell Host and Microbe

JF - Cell Host and Microbe

IS - 5

ER -

Supplementation with a probiotic mixture accelerates gut microbiome maturation and reduces intestinal inflammation in extremely preterm infants

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this